[Retrovesical recurrence of renal cell carcinoma 14 years after laparoscopic nephrectomy: a case report]. / Retrovesikales Rezidiv eines Nierenzellkarzinoms 14 Jahre nach laparoskopischer Nephrektomie. Ein Fallbericht.

Local recurrence or metachronous distant metastasis of renal cell carcinoma mostly occurs in the first five years after radical or partial nephrectomy. Nevertheless, late local recurrences or metachronous metastases are regularly observed. The most common metastatic sites are lung and bones, although unusual metastatic sites are also possible. We present the case of a 70-year-old patient with a solitary recurrence of a clear renal cell carcinoma in retrovesical location after a relapse-free survival of 14 years. We performed cystoprostatectomy with an ileal conduit, resecting the tumour completely (in sano). The long-term prognosis of the patient cannot be estimated as yet.Despite the fact that a solitary and very late recurrence of a renal cell carcinoma in retrovesical location is extremely rare, late recurrence is a specific characteristic of renal cell carcinoma. Therefore, long-term follow-up for at least 15 years is required. Curative surgical resection is the treatment of choice for such late solitary recurrences.

Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).

BACKGROUND: Recent publications suggest a benefit from surgical removal of urothelial carcinoma metastases (UCM) for a subgroup of patients. OBJECTIVE: We report the combined experience and outcome of patients undergoing resection of UCM gained at 15 uro-oncologic centers in Germany. DESIGN, SETTING, AND PARTICIPANTS: Retrospective survey of 44 patients with distant UCM of the bladder or upper urinary tract who underwent complete resection of all detectable metastases in 15 different German uro-oncological centers between 1991 and 2008. INTERVENTION: Resected metastatic sites were the following: retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%). Systemic chemotherapy was administered in 35 of 44 patients (79.5%) before and/or after UCM surgery. MEASUREMENTS: Overall, cancer-specific and progression-free survival from time of diagnosis and metastasectomy of UCM. RESULTS AND LIMITATIONS: Median survival from initial diagnosis of UCM and subsequent resection was as follows: overall survival, 35 mo and 27 mo; cancer-specific survival, 38 mo and 34 mo; and progression-free survival, 19 mo and 15 mo. Overall 5-yr survival from metastasectomy for the entire cohort was 28%. Seventeen patients were still alive without progression at a median follow-up of 8 mo. Seven patients without disease progression survived for >2 yr and remained free from tumor progression at a median follow-up of 63 mo. No significant prognostic factors could be determined due to the limited patient number. CONCLUSIONS: Long-term cancer control and possible cure can be achieved in a subgroup of patients following surgical removal of UCM. Metastasectomy in patients with disseminated UCM remains investigational and should only be offered to those with limited disease as a combined-modality approach with systemic chemotherapy.